Table 1.

Logistic regression analysis of association between baseline factors and clinical and radiographic outcomes at Week 52 in patients assigned to the PB0 + MTX treatment arm

	SDAI remission Odds ratio 95% CI P value		cRRP Odds ratio 95% CI P value
	Univariate	Multivariate	Univariate	Multivariate
DAS28‐ESR	0.56 0.41‐0.77 <.001	0.57 0.38‐0.86 .007	2.03 1.33‐3.1 .001	1.39 0.74‐2.59 .302
HAQ‐DI	0.52 0.31‐0.88 .016	0.94 0.48‐1.83 .847	2.49 1.33‐4.65 .004	1.38 0.57‐3.35 .475
mTSS	0.82 0.59‐1.14 .229	‐	2.04 1.38‐3.02 <.001	2.02 1.3‐3.17 .002
RF	1.06 0.77‐1.45 .728	‐	1.51 0.97‐2.36 .068	1.18 0.74‐1.87 .492
Anti‐CCP antibody	0.88 0.59‐1.3 .509	‐	0.94 0.56‐1.56 .801	‐
MMP‐3	0.89 0.63‐1.27 .530	‐	1.82 1.14‐2.9 .012	1.00 0.54‐1.86 .989
TNFα	1.0 0.69‐1.65 .778	‐	1.16 0.69‐1.95 .576	‐
IL‐6	0.8 0.61‐1.05 .109	‐	1.98 1.32‐2.96 <.001	1.61 0.95‐2.72 .077

Abbreviations: CCP, cyclic citrullinated peptide; cRRP, clinically relevant radiographic progression; CZP, certolizumab pegol; DAS28‐ESR, Disease Activity Score of 28 joints ‐ erythrocyte sedimentation rate; HAQ‐DI, Health Assessment Questionnaire Disability Index; IL‐6, interleukin 6; MMP‐3, matrix metalloproteinase; mTSS, van der Heijde modified total Sharp score; MTX, methotrexate; PBO, placebo; RF, rheumatoid factor; SDAI, simple disease activity index; TNFα, tumor necrosis factor α.